The acceptable safety profile and longer t1/2 of WBP216, which allows for a less frequent administration compared to other IL-6 inhibitors, could provide a new therapeutic option to the clinicians for the treatment of patients with RA. This evidence concerns the gene IL6 and rheumatoid arthritis.